|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
101.95(B) |
Last
Volume: |
351,356 |
Avg
Vol: |
769,142 |
52
Week Range: |
$692.45 - $993.35 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
24,729 |
84,192 |
120,701 |
282,978 |
Total Sell Value |
$23,631,267 |
$76,701,012 |
$107,160,703 |
$220,505,683 |
Total People Sold |
7 |
13 |
15 |
17 |
Total Sell Transactions |
14 |
38 |
55 |
116 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fenimore Christopher R. |
SVP Controller |
|
2022-10-26 |
4 |
GA |
$0.00 |
$0 |
I/I |
871 |
460 |
|
- |
|
Fenimore Christopher R. |
SVP Controller |
|
2022-10-26 |
4 |
GD |
$0.00 |
$0 |
I/I |
871 |
0 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2022-10-17 |
4 |
AS |
$739.50 |
$264,741 |
D/D |
(358) |
28,744 |
|
5% |
|
Landry Robert E |
EVP Finance CFO |
|
2022-10-14 |
4 |
D |
$743.78 |
$849,397 |
D/D |
(1,142) |
29,102 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2022-10-14 |
4 |
OE |
$381.92 |
$572,880 |
D/D |
1,500 |
30,244 |
|
- |
|
Fenimore Christopher R. |
SVP Controller |
|
2022-10-05 |
4 |
AS |
$749.00 |
$1,381,156 |
D/D |
(1,844) |
16,425 |
|
-1% |
|
Vagelos P Roy |
Director |
|
2022-10-03 |
4 |
GD |
$0.00 |
$0 |
I/I |
304 |
126,043 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2022-10-03 |
4 |
AS |
$705.39 |
$775,929 |
D/D |
(1,100) |
19,644 |
|
3% |
|
Mccourt Marion |
EVP Commercial |
|
2022-10-03 |
4 |
OE |
$342.93 |
$394,941 |
D/D |
1,100 |
20,144 |
|
- |
|
Fenimore Christopher R. |
SVP Controller |
|
2022-10-03 |
4 |
AS |
$724.00 |
$2,422,504 |
D/D |
(3,346) |
18,269 |
|
3% |
|
Ryan Arthur F |
Director |
|
2022-10-03 |
4 |
AS |
$705.39 |
$72,654 |
D/D |
(100) |
19,482 |
|
3% |
|
Thompson Craig B. |
Director |
|
2022-10-03 |
4 |
A |
$0.00 |
$0 |
D/D |
279 |
279 |
|
- |
|
Tessier-Lavigne Marc |
Director |
|
2022-10-03 |
4 |
AS |
$718.00 |
$2,593,416 |
D/D |
(3,612) |
2,269 |
|
3% |
|
Tessier-Lavigne Marc |
Director |
|
2022-10-03 |
4 |
OE |
$413.33 |
$1,492,948 |
D/D |
3,612 |
5,881 |
|
- |
|
Tessier-Lavigne Marc |
Director |
|
2022-09-30 |
4 |
AS |
$698.00 |
$2,392,744 |
D/D |
(3,428) |
2,269 |
|
11% |
|
Tessier-Lavigne Marc |
Director |
|
2022-09-30 |
4 |
OE |
$413.33 |
$1,416,895 |
D/D |
3,428 |
5,697 |
|
- |
|
Tessier-Lavigne Marc |
Director |
|
2022-09-29 |
4 |
AS |
$686.89 |
$2,624,684 |
D/D |
(3,798) |
2,269 |
|
10% |
|
Tessier-Lavigne Marc |
Director |
|
2022-09-29 |
4 |
OE |
$413.33 |
$1,569,827 |
D/D |
3,798 |
6,067 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2022-09-12 |
4 |
AS |
$709.93 |
$3,364,111 |
D/D |
(4,696) |
30,578 |
|
2% |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2022-09-09 |
4 |
D |
$730.96 |
$25,805,812 |
D/D |
(35,304) |
35,274 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2022-09-09 |
4 |
OE |
$555.67 |
$22,226,800 |
D/D |
40,000 |
70,578 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2022-09-09 |
4 |
D |
$730.96 |
$15,152,801 |
D/D |
(20,730) |
20,850 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2022-09-09 |
4 |
OE |
$270.43 |
$8,112,900 |
D/D |
30,000 |
41,580 |
|
- |
|
Bassler Bonnie L |
Director |
|
2022-09-09 |
4 |
AS |
$741.00 |
$451,269 |
D/D |
(609) |
1,082 |
|
1% |
|
Bassler Bonnie L |
Director |
|
2022-09-09 |
4 |
OE |
$376.69 |
$229,404 |
D/D |
609 |
1,691 |
|
- |
|
1366 Records found
|
|
Page 12 of 55 |
|
|